Journal of Clinical Endocrinology & Metabolism, Vol 64, 1021-1026, Copyright © 1987 by Endocrine Society

ARTICLES

Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea

J Schlechte, G el-Khoury, M Kathol and L Walkner

To determine whether women with PRL-secreting pituitary tumors have similar decreases in cortical and trabecular bone and to determine whether bone loss associated with hyperprolactinemia is reversible, we measured forearm and vertebral bone mineral in normal women and in amenorrheic women with treated and untreated hyperprolactinemia. The mean spinal bone mineral content in hyperprolactinemic women [130 +/- 23 (+/- SD) mg/mL] was 25% lower than that in normal women (167 +/- 28 mg/mL), while the mean forearm bone mineral content (0.71 +/- 0.04 g/cm2) was similar to that in normal women (0.73 +/- 0.05 g/cm2). Women with normal serum PRL levels and regular menses after transsphenoidal surgery had slightly higher mean spinal bone mineral content (149 +/- 28 mg/mL) than women who remained amenorrheic after surgery (129 +/- 19 mg/mL), but the mean value in the cured women remained significantly lower than that in normal women. In contrast, women who had undergone successful transsphenoidal pituitary surgery had mean forearm bone mineral comparable to that in normal women. There was no correlation between vertebral and radial bone mineral in hyperprolactinemic women and no correlation between bone mineral and serum PRL, serum estradiol, or duration of amenorrhea when age was taken into account. These findings suggest that hyperprolactinemia and/or decreased gonadal function in women with PRL-secreting pituitary tumors are associated with more prominent effects on trabecular bone in the spine than on cortical bone in the wrist. In addition, the abnormal spinal bone mineral content after successful treatment suggest that normalization of estradiol and PRL secretion is not sufficient to restore bone mineral content to normal, although it may be stabilized.

This article has been cited by other articles:

				M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao Advances in the Treatment of Prolactinomas Endocr. Rev., August 1, 2006; 27(5): 485 - 534. [Abstract] [Full Text] [PDF]

				J. A. Schlechte Prolactinoma N. Engl. J. Med., November 20, 2003; 349(21): 2035 - 2041. [Full Text] [PDF]

				A. WIECK and P. M. HADDAD Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences: Selective literature review The British Journal of Psychiatry, March 1, 2003; 182(3): 199 - 204. [Abstract] [Full Text] [PDF]

				M J Tansey and J A Schlechte Pituitary production of prolactin and prolactin-suppressing drugs Lupus, October 1, 2001; 10(10): 660 - 664. [Abstract] [PDF]

				D. Coss, L. Yang, C. B. Kuo, X. Xu, R. A. Luben, and A. M. Walker Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat Am J Physiol Endocrinol Metab, December 1, 2000; 279(6): E1216 - E1225. [Abstract] [Full Text] [PDF]

				K. K. Miller and A. Klibanski Amenorrheic Bone Loss J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1775 - 1783. [Full Text]

				C. Di Somma, A. Colao, A. Di Sarno, M. Klain, M. L. Landi, G. Facciolli, R. Pivonello, N. Panza, M. Salvatore, and G. Lombardi Bone Marker and Bone Density Responses to Dopamine Agonist Therapy in Hyperprolactinemic Males J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 807 - 813. [Abstract] [Full Text]